logo
919-206-7900
Polarean Imaging plc.'s technology is for research use only

Board of Directors

Jonathan Allis
Non-Executive Chairman

Jonathan Allis joined the board of the Group as a Non-Executive Director in September 2017 and assumed the role of Chairman in February 2020. Dr Allis is the founding Chief Executive Officer of Blue Earth Diagnostics. Prior to this role, Dr Allis was the General Manager for PET at GE Healthcare Life Sciences and had global responsibility for GE Healthcare's PET agent and PET synthesis platforms business. He has previously held positions in research and development, marketing and product development at GE Healthcare, Amersham plc., Siemens Medical Solutions and Oxford Magnet Technology in the UK, USA and Germany.

Dr Allis has an undergraduate degree in physics from the University of Cape Town and a doctorate in biochemistry from the University of Oxford.

Dr Allis is considered to be independent from the Group's other Directors and Shareholders at the time of Admission.

Richard Hullihen
Chief Executive Officer

Richard Hullihen began his career with GEC-Picker International in the start-up and formation of their CT and MRI businesses, holding key positions in engineering and programme management before moving into corporate business development and strategic planning. He also set up joint ventures in Japan for the production of MRI systems. Mr Hullihen led the acquisition of Instrumentarium's MRI business and was then Director of Development for the parent organisation, leading enterprise wide strategic planning and representing the medical business at the corporate level in Marconi Medical Systems, Inc. That led to the start-up of Marconi's healthcare informatics business where Mr Hullihen was Vice President and General Manager. Following that, Mr Hullihen became the Chief Executive Officer of m2m, specialising in the development of high performance cryogenic and superconducting RF coils for magnetic resonance systems.

Mr Hullihen holds a Bachelor of Science degree in electrical engineering from Western Michigan University and an MBA from Case Western Reserve University.

Kenneth West
Chief Operating Officer

Ken West began his career with Fortune 200 FMC Corporation in the 1980s, and since that time he has been involved at a senior level with five successful new companies in the medical technology field.

Mr West held senior management positions at three venture-capital backed start-ups, including Vice President of Sales, Marketing and Business Development at Embrex, Inc., a drug delivery company that went public and was acquired by Pfizer, Inc., Chief Operating Officer at VetInsite, a health care information technology company that was acquired by MediMedia and Biolex, a transgenic protein company, where he was a co-founder and the first President/Chief Operating Officer. The company raised more than US$180 million in venture capital and was acquired by Synthon BV. Mr West has also led the US subsidiaries of two European medical device companies as they entered the US market, including Curasan AG and Tem International GmbH. As President of each of these US companies, Mr West built and managed the US organisations, growing them into multi-million dollar subsidiaries with direct sales forces to physician offices and hospitals.

Mr West holds a Bachelor of Science degree in chemical engineering from Cornell University and an MBA from the Wharton School of the University of Pennsylvania.

Bastiaan Driehuys, Ph.D.
Chief Technology Officer

Bastiaan Driehuys invented hyperpolarised gas MRI while completing his Doctorate in Atomic Physics at Princeton University. In 1996, Dr Driehuys helped to start MITI, a company founded to commercialise hyperpolarised gas technology. In 1999, Dr Driehuys became Chief Executive Officer of the company, managed its acquisition for US$15 million by Amersham and he remained with the company as Director of the Research Triangle Park Facility until 2003. In this senior management position he oversaw all hyperpolarised gas physics and applications research. He served on the Amersham Global Imaging Management Team, which was broadly responsible for the company's diagnostic imaging research efforts for all modalities and disease areas. In 2004, Dr Driehuys returned to academia at Duke University, where he is now a Professor of Radiology, Medical Physics and Biomedical Engineering. His research programme has been focused on driving the clinical translation of HPX MRI and exploiting the unique properties of this atom for functional and molecular imaging.

Dr Driehuys completed his Ph.D. in Atomic Physics and his post-doctoral work at Princeton University after receiving his BA summa cum laude in physics from Franklin & Marshall College in Lancaster, Pennsylvania.

He has authored more than 50 publications in the areas of hyperpolarisation physics and biological applications. He holds 32 granted US patents and is a co-recipient of the Thomas Alva Edison Patent Award, as well as the Tibbetts Award for Outstanding Small Business Scientific Accomplishment.

Juergen Laucht
Non-Executive Director

Juergen Laucht has over 40 years of business experience in the chemical engineering industry. In 2011 Mr Laucht took on the role of Managing Director of NUKEM Isotopes, prior to which he was the General Manager for Research Reactors & Stable Isotopes for NUKEM. Prior to joining NUKEM in 1995, Mr Laucht held positions at Siemens in their Fuel Fabrication Works team and at Reactor Brennelement Union, both in Germany.

Mr Laucht has a degree in Chemical Engineering from the Technical University of Darmstadt, Germany.

Cyrille Petit
Non-Executive Director

Cyrille Petit began his career at Goldman Sachs and went on to specialise in external growth, mergers and acquisitions, and strategy at General Electric, where he worked for 15 years. In 2012, he joined the executive committee of Smith & Nephew PLC as Chief Corporate Development Officer, and later added the responsibilities of President, Global Business Services. There, he led the group’s transformation and helped to accelerate growth through a series of transactions worth in excess of US$3B

Page last updated: 01 June 2020